Takeda’s dengue vaccine obtains WHO prequalification

2024-05-16

交易

疫苗引进/卖出免疫疗法临床研究紧急使用授权

Takeda’s dengue vaccine obtains WHO prequalification

Preview

来源: Pharmaceutical Technology

The WHO recommended the vaccine’s use for children aged six to 16 years in areas with a high burden of dengue and transmission. Credit: chemical industry / Shutterstock.com.

Takeda’s new dengue vaccine, TAK-003, has received prequalification from the World Health Organization (WHO).

TAK-003 is the second dengue vaccine to achieve this status.

WHO has recommended the use of the new vaccine for children aged six to 16 years in areas with a high burden of dengue and transmission.

A live-attenuated vaccine, TAK-003 includes weakened forms of all four serotypes of the dengue virus.

It is designed to be administered in a two-dose regimen with an interval of three months between doses.

See Also:Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine by CanSino Biologics for Neisseria meningitidis Infections: Likelihood of Approval

Preview

来源: Pharmaceutical Technology

Vaccine for Acne Vulgaris by Sanofi for Acne Vulgaris: Likelihood of Approval

Preview

来源: Pharmaceutical Technology

Sanofi Pasteur’s CYD-TDV dengue vaccine had previously received the WHO prequalification.

Dengue, a mosquito-borne disease, poses a significant health threat with an estimated 100 to 400 million cases annually.

The disease is prevalent in Asia, Africa and the Americas, with the WHO region of the Americas reporting 4.5 million cases and 2,300 deaths in 2023 alone.

WHO regulation and prequalification director Dr Rogerio Gaspar stated: “The prequalification of TAK-003 is an important step in the expansion of global access to dengue vaccines, as it is now eligible for procurement by UN agencies including UNICEF and PAHO.

“With only two dengue vaccines to date prequalified, we look forward to more vaccine developers coming forward for assessment so that we can ensure vaccines reach all communities who need it.”

Earlier this month, Takeda entered an exclusive worldwide option and licence agreement with AC Immune for an Alzheimer’s disease immunotherapy in a $2.2bn deal.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构